Canada - français - Health Canada

advanced vision research, inc. - polyéthylène glycol 400; propylène glycol - solution - 0.4%; 0.3% - polyéthylène glycol 400 0.4%; propylène glycol 0.3% - eent drugs, miscellaneous

Canada - français - Health Canada

advanced vision research, inc. - carboxyméthylcellulose sodique - solution - 0.5% - carboxyméthylcellulose sodique 0.5% - artificial tears

Union européenne - français - EMA (European Medicines Agency)

advanced accelerator applications - edotreotide - neuroendocrine tumors; radionuclide imaging - produits radiopharmaceutiques de diagnostic - ce médicament est destiné à un usage diagnostique uniquement. après où elles sont radiomarquées avec gallium (68ga) de chlorure de solution, la solution de gallium (68ga) edotreotide obtenu est indiqué pour la tomographie par Émission de positons (tep) des récepteurs de la somatostatine surexpression dans les patients adultes avec des cas confirmés ou suspects de bien différenciés gastro-enteropancreatic les tumeurs neuroendocrines (gep-net) pour la localisation de tumeurs primaires et de leurs métastases.

Union européenne - français - EMA (European Medicines Agency)

advanced accelerator applications - lutétium (177lu) oxodotréotide - tumeurs neuroendocrines - autres produits radiopharmaceutiques thérapeutiques - lutathera est indiqué pour les traitement des non résécable ou métastatique, progressive, bien différenciée (g1 et g2), somatostatine récepteur positif certification tumeurs neuroendocrines (gep‑nets) chez l’adulte.

Union européenne - français - EMA (European Medicines Agency)

advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - radiolésions - detoxifying agents for antineoplastic treatment - lysakare est indiqué pour la réduction de la fonction rénale l'exposition aux rayonnements pendant peptidique-récepteur de la thérapie par radionucléides (prrt) avec le lutécium (177lu) oxodotreotide chez les adultes.

Union européenne - français - EMA (European Medicines Agency)

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agents antinéoplasiques - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Canada - français - Health Canada

advanced dosage forms inc. - alprostadil - solution - 500mcg - alprostadil 500mcg - miscellaneous vasodilatating agents

Union européenne - français - EMA (European Medicines Agency)

a.c.o.m. - advanced center oncology - chlorure de cuivre (64cu) - imagerie des radionucléides - various diagnostic radiopharmaceuticals - cuprymina est un précurseur radiopharmaceutique. il n'est pas destiné à une utilisation directe chez les patients. ce médicament doit être utilisé que pour le marquage de molécules de transporteurs, qui ont été spécifiquement développés et autorisés pour radiomarquage avec ce radionucléide.

Canada - français - Health Canada

body gold, a division of pep products, inc. - vitamine b6 (chlorhydrate de pyridoxine); acide d-pantothénique; manganèse (gluconate de manganèse); chrome (hexanicotinate d'inositol); choline (bitartrate de choline); inositol - capsule - 4mg; 15mg; 1mg; 50mcg; 15mg; 15mg - vitamine b6 (chlorhydrate de pyridoxine) 4mg; acide d-pantothénique 15mg; manganèse (gluconate de manganèse) 1mg; chrome (hexanicotinate d'inositol) 50mcg; choline (bitartrate de choline) 15mg; inositol 15mg - vitamins & minerals

Canada - français - Health Canada

colgate-palmolive canada inc - fluorure de sodium; triclosan; dioxyde de silicium - pâte dentifrice - 0.243%; 0.3%; 5% - fluorure de sodium 0.243%; triclosan 0.3%; dioxyde de silicium 5% - dental agents